Log In

 

Company Name : Boehringer Ingelheim

Thursday, March 1, 2018 11:59PM IST (6:29PM GMT)

(BW)(BOEHRINGER-INGELHEIM)

Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’


Rare Disease Day draws attention to the importance of early diagnosis and treatment of IPF.; Even though international guidelines recommend to offer antifibrotic treatment to the majority of individuals with IPF, research in Europe shows that around 40% of patients with confirmed IPF do not receive antifibrotic treatment.1; Boehringer Ingelheim provides physicians with insights into progression of IPF as well as the benefits of early diagnosis and intervention.


Ingelheim, Germany

On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the question: ‘Why wait in IPF?´ while awareness activities are focussing on highlighting the benefits of early diagnosis and considering early treatment of idiopathic pulmonary fibrosis (IPF). IPF is a rare, debilitating and fatal lung disease which affects approximately 3 million people worldwide.2

 

Diagnosing IPF can be difficult because typically, patients with IPF present with nonspecific symptoms usually attributed to ageing, deconditioning or other comorbidities.2 The median time from first symptoms to diagnosis is around two years.3 Early and accurate diagnosis of IPF is important, as interventions such as antifibrotic therapies, supplemental oxygen treatment, cough management and pulmonary rehabilitation may help patients to better manage their condition.

 

In IPF a key concern is that many patients who are diagnosed with the disease remain untreated. In 2016, 290 respiratory physicians from five European countries participated in an online survey about IPF treatment in patients under their care. The survey showed that, of patients with a confirmed diagnosis, 40% did not receive treatment.1

 

IPF is unpredictable and damage is permanent.Without appropriate medical intervention the opportunity to slow disease progression is lost. “Slowing disease progression and preserving lung function by reducing decline should be the primary goal for all physicians when treating individuals with IPF. For this reason, initiation of treatment at diagnosis is vital”, commented Professor Toby Maher, Royal Brompton Hospital, UK.

 

While a cure for IPF has not been found yet, two approved antifibrotic drugs shown to slow disease progression in IPF are recommended for the majority of patients by international guidelines.4 At the time of diagnosis, IPF patients should feel empowered to take an active approach to managing their disease by learning all they can about it, and discussing with their treating physicians what treatment options and approaches are available.

 

New resources released for Rare Disease Day can be found at Boehringer-Ingelheim.com.

 

More information on IPF for physicians can be found at inIPF. Further information for patients can be found at Life with IPF.

 

~ ENDS ~

 

Please click on the link below for ‘Notes to Editors’ and ‘References’:

 

https://www.boehringer-ingelheim.com/press-release/IPFwhywait

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com


More News from Boehringer Ingelheim

27/11/2018 1:38PM

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in ...

16/11/2018 1:10PM

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Boehringer Ingelheim Expands Biomarker-driven Oncology Programs Alliance EnhancesEpizyme’s Leadership in Oncology Epigenetics Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) announced a new ...

05/11/2018 6:07PM

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1 Effect of empagliflozin on HHF was ...

Similar News

14/12/2018 5:15PM Image

Recognize Mental Health as First Public Health Challenge, Says Dr. Prakriti Poddar, at Launch of Poddar Wellness Ltd

With the vision to reach over 10 lakh people through online and offline modes, leading mental health space leader, Dr. Prakriti Poddar, launched Poddar Wellness Ltd in an event graced by Guest of Honour PM-JAY CEO Dr. ...

No Image

14/12/2018 4:58PM

With 72 Percent Employee Rating, Automobiles Is the Most Loved Sector to Work For: JobBuzz Workplace Index OND 2018 Report

Automobiles is one of the most preferred sectors for employment and for good reasons. JobBuzz Workplace Index, which tabulates the employee sentiments as comparable percentages, revealed that most (72%) employees ...